The Patent Finder

Calydon, Inc.

Also on record
Records under this name other than patents Calydon, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Calydon, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 6,692,736Cell-specific adenovirus vectors comprising an internal ribosome entry site
Formerly held
Term ended
Term ended Jul 16, 2021 · USPTO record
Term endedTerm ended Jul 16, 2021USPTO record
US 6,991,935Target cell-specific adenoviral vectors containing E3 and methods of use thereof
Formerly held
Term ended
Term ended Aug 7, 2020 · USPTO record
Term endedTerm ended Aug 7, 2020USPTO record
US 6,495,130Target cell-specific adenoviral vectors containing E3 and methods of use thereof
Formerly held
Term ended
Ended no later than Dec 29, 2019 · USPTO record
Term endedEnded no later than Dec 29, 2019USPTO record
US 7,575,919Adenovirus vectors containing cell status-specific response elements and methods of use thereof
Formerly held
Term ended
Ended no later than Sep 9, 2019 · USPTO record
Term endedEnded no later than Sep 9, 2019USPTO record
US 6,432,700Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
Formerly held
Term ended
Ended no later than Mar 2, 2018 · USPTO record
Term endedEnded no later than Mar 2, 2018USPTO record
US 6,916,918Human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
Formerly held
Lapsed on the fee record
Ended Jul 12, 2013 · USPTO record
Lapsed on the fee recordEnded Jul 12, 2013USPTO record
US 6,254,862Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
Formerly held
Lapsed on the fee record
Ended Jul 3, 2013 · USPTO record
Lapsed on the fee recordEnded Jul 3, 2013USPTO record
US 6,911,200Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
Lapsed on the fee record
Ended Jun 28, 2013 · USPTO record
Lapsed on the fee recordEnded Jun 28, 2013USPTO record
US 6,197,293Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
Formerly held
Lapsed on the fee record
Ended Mar 6, 2013 · USPTO record
Lapsed on the fee recordEnded Mar 6, 2013USPTO record
US 6,852,528Human and mouse uroplakin II gene transcriptional regulatory elements
Formerly held
Lapsed on the fee record
Ended Feb 8, 2013 · USPTO record
Lapsed on the fee recordEnded Feb 8, 2013USPTO record
10 of 27 patents shown.
Pro members see all 27.
Pro members: see all 27 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited